Investigator

Emanuele Zucca

Deputy Head · Oncology Institute of Southern Switzerland, Division of Research

Research Interests

EZEmanuele Zucca
Papers(1)
Superior prognostic a…
Collaborators(3)
Maria Cristina PirosaMaria Elena CabreraSara Steffanoni
Institutions(3)
Ente Ospedaliero Cant…University Of ChileOspedale Valduce

Papers

Superior prognostic accuracy of FIGO staging system in primary female genital tract lymphomas: A retrospective study (IELSG35)

Abstract Primary lymphoma of the female genital tract (PLFGT) is a rare type of extranodal lymphoma. In this retrospective study from the International Extranodal Lymphoma Study Group, we analyzed clinical data from 60 women diagnosed with PLFGT between 1982 and 2012. The median age was 52 years. Limited stage, as defined by the Ann Arbor and FIGO staging systems, was observed in 55% and 63% of cases, respectively. The uterus was the primary site of lymphoma in 25 cases, with the ovaries as the second most common site ( n  = 24). The most common histological subtype was diffuse large B‐cell lymphoma (DLBCL, n  = 44), followed by follicular lymphoma and marginal zone lymphoma (6 patients each). Two patients received surgery alone as first‐line therapy, while 58 underwent systemic therapy, 16 following major surgery. Thirteen patients received consolidation radiotherapy and six were given central nervous system (CNS) prophylaxis. Twenty patients had disease progression or recurrence. Six patients with DLBCL (14%) experienced CNS relapse, which was the only site of recurrence in five of them. All but one patient with CNS relapse had primary ovarian involvement, and three had bulky disease; none of these patients had received CNS prophylaxis. With a median follow‐up of 60 months, the median overall survival of the DLBCL cohort was approximately 13 years, with a 5‐year survival rate of 77%. In multivariable analysis, advanced disease according to the FIGO system was the only parameter significantly associated with shorter overall, cause‐specific, and progression‐free survival in patients with DLBCL.

321Works
1Papers
3Collaborators
PrognosisNeoplasm StagingNeoplasm Recurrence, LocalCentral Nervous System NeoplasmsTumor MicroenvironmentDisease-Free SurvivalGenital Neoplasms, Female

Positions

Deputy Head

Oncology Institute of Southern Switzerland · Division of Research

Group Leader

IOR Insitute of Oncology Research · International Extranodal Lymphoma Study Group

2020–

Researcher

Università della Svizzera italiana Facoltà di scienze biomediche

2017–

Researcher

University of Bern · Department of Medical Oncoogy, Inselspital Bern Univesity Hospital

Country

CH